Sector
PharmaceuticalsOpen
₹3,180.9Prev. Close
₹3,180.9Turnover(Lac.)
₹8,704.92Day's High
₹3,233Day's Low
₹3,16552 Week's High
₹3,590.752 Week's Low
₹2,755.9Book Value
₹257.56Face Value
₹5Mkt Cap (₹ Cr.)
1,09,201.29P/E
57.3EPS
56.3Divi. Yield
0.99On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 169.23 | 169.23 | 84.62 | 84.62 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 6,659.53 | 6,286.73 | 6,260.8 | 5,945.48 |
Net Worth | 6,828.76 | 6,455.96 | 6,345.42 | 6,030.1 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 6,742.32 | 6,450.57 | 6,168.44 | 4,248.24 |
yoy growth (%) | 4.52 | 4.57 | 45.19 | -7.49 |
Raw materials | -1,907.5 | -1,669.67 | -1,637.45 | -1,115.69 |
As % of sales | 28.29 | 25.88 | 26.54 | 26.26 |
Employee costs | -1,097.93 | -1,097.12 | -1,061.76 | -826.07 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 1,466.21 | 1,366.11 | 1,116.77 | 562.13 |
Depreciation | -602.43 | -609.84 | -606.66 | -383.88 |
Tax paid | -474.76 | -228.26 | -178.26 | -80.09 |
Working capital | -48.68 | 274.86 | 692.18 | 68.94 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 4.52 | 4.57 | 45.19 | -7.49 |
Op profit growth | -4.15 | 14.33 | 111.26 | -19.49 |
EBIT growth | 0.13 | 9.88 | 80.79 | -26.05 |
Net profit growth | -12.86 | 21.24 | 94.69 | -43.56 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 11,317 | 10,562 | 9,464 | 8,419 | 7,886 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 11,317 | 10,562 | 9,464 | 8,419 | 7,886 |
Other Operating Income | 199 | 166 | 156 | 89 | 119 |
Other Income | 23 | 146 | 45 | 197 | 57 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.6 | 93.59 | 4,00,808.91 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,586.5 | 79.14 | 1,74,808.41 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,510 | 25.34 | 1,21,963.88 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,341.6 | 20.92 | 1,11,903.46 | 1,200.7 | 0.6 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,226.7 | 57.3 | 1,09,169.13 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman Emeritus
Sudhir Mehta
Executive Chairman
Samir Mehta
Independent Director
Ameera Shah
Independent Director
Nayantara Bali
Director (Operation)
Jinesh Shah
Independent Director
Maurice Chagnaud
Whole Time Director
Aman Mehta
Independent Director
Manish Choksi
Company Sec. & Compli. Officer
Chintan Trivedi
Independent Director
Nikhil Khattau
Non Executive Director
Jindal Mehta
Torrent House,
Off Ashram Road,
Gujarat - 380009
Tel: 91-79-26599000
Website: http://www.torrentpharma.com
Email: investorservices@torrentpharma.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Torrent Pharmaceuticals Limited is a leading player in the Indian pharmaceutical sector, concentrating on the chronic and sub-chronic therapeutic segments. The Company has established itself as a lead...
Read More
Reports by Torrent Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.